Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Simeprevir and Eltrombopag as Potential Inhibitors of SARS-CoV2 Proteases: A Molecular Docking and Virtual Screening Approach to Combat COVID-19

21 September 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The present study investigates the binding affinities of 61 FDA approved drugs against two key proteases of SARS-COV2, 3-chymotrypsin-like protease and papain-like protease. We also investigated the ADMET properties of the top 10 best binding drugs to understand the druglikeness property.

Keywords

Simeprevir
Eltrombopag
COVID-19
SARS-CoV2
Proteases
Docking
ADMET

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Sep 21, 2020 Version 1

Version Notes

Final draft

Metrics

2,381
569
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12980306.v1
D O I: 10.26434/chemrxiv.12980306.v1 [opens in a new tab]

Funding

The present study do not have any specific funding

Author’s competing interest statement

Author do not have any conflict of interest

Share